Navigating Institutional Barriers: Inventory Management and EHR Pathways in Endometrial Cancer

In ‘Navigating Institutional Barriers: Inventory Management and EHR Pathways in Endometrial Cancer,’ the expert Oncology Pharmacists examined the following critical questions:

How can inventory management and formulary restrictions with immunotherapies in endometrial cancer influence prescribing decisions?

How can the pharmacist aid in overcoming these?

In what ways might electronic health records contribute to outdated treatment pathways in endometrial cancer?

Led by the moderator, Megan May, the expert oncology pharmacists discussed the impact of institutional standards and health inequities on the availability of various immunotherapies. The panel emphasized the vital role of the pharmacist in Pharmacy and Therapeutics (P&T) committees to advocate for diverse therapeutic toolboxes and manage inventory to prevent drug substitutions during stock-outs. The experts also explored the transition to subcutaneous pembrolizumab, highlighting its potential to save chair time and improve access for patients in satellite centers during the maintenance phase. Additionally, the pharmacists addressed the challenges of rapidly evolving data, noting that EHR pathways can quickly become outdated as new results from clinical trials and FDA approvals emerge.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Clinical Realities of Biomarker Utilization in Advanced Endometrial Cancer, further explores endometrial cancer, highlighting the pharmacist's role in advocating for biomarker testing and the specific patient factors that guide immunotherapy selection.